secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001104659-23-040848
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia and GSK restructure PRINT license; Liquidia gains rights for most inhaled uses
--------------------------------------------------------------------------------

- New non-exclusive, royalty-free license replaces 2012 collaboration; GSK gets pre-clinical research rights only.
- Liquidia may apply PRINT to all inhaled formulations except certain GSK proprietary molecules.
- GSK must seek expanded license for clinical/commercial use; Liquidia retains ownership of its technology.
- Agreement effective March 31, 2023; press released April 3, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923040848/0001104659-23-040848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465923040848/tm2311372d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-040848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer